Table 1.
Systematic review of toxicity literature data according to PRISMA statement.
| Trials (First Author) | Ref | Year | Design type | Tumor type | Population | N. of patients | Treatment | Toxicity | Follow up |
|---|---|---|---|---|---|---|---|---|---|
| Murayama D. | (32) | 2022 | retrospective study | anaplastic thyroid cancer | Asiatic | 1 | lenvatinib | lung cavitations | + |
| Kawanishi Y. | (33) | 2020 | case report | hepatocellular carcinoma | Asiatic | 1 | lenvatinib | pneumothorax | until death |
| Gennatas S. | (34) | 2013 | case report | lung adenocarcinoma | Caucasic | 1 | crizotinib | pneumothorax | – |
| Mori M. | (31) | 2005 | case report | lung adenocarcinoma | Asiatic | 1 | gefitinib | pneumothorax | + |
| Yang S.H. | (36) | 2010 | case report | colorectal adenocarcinoma | NS | 1 | bevacizumab and CHT | pneumothorax | – |
| Wang R. | (35) | 2020 | case report | lung adenocarcinoma | Asiatic | 1 | pembrolizumab | hemoptysis and cavitations | until death |